Matinas BioPharma reports 2023 net loss $22.9M; cash runway only through Q3 2024

Matinas BioPharma Holdings, Inc.

Revenue fell to $1.1M from $3.2M; net loss per share $0.11 vs $0.10 prior year.
Cash and equivalents $13.8M at Dec 31, 2023, down from $28.8M; company sees funding only through Q3 2024.
FDA agreed on design of single Phase 3 ORALTO trial for MAT2203 in invasive aspergillosis.
Compassionate use program: 19 patients enrolled; most with renal recovery after switching from AmBisome; 8 completed with complete resolution.
Preclinical LNC-docetaxel shows comparable efficacy to IV-docetaxel with no weight loss in mice.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Matinas BioPharma Holdings, Inc. reported financial results for for the year and quarter ended December 31, 2023.

Period: for the year and quarter ended December 31, 2023
Result: reported results

Exact text from the filing

On March 27, 2024, Matinas BioPharma Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the year and quarter ended December 31, 2023.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Matinas BioPharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-011509

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.